A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL

ClinicalTrials.gov ID: NCT02518113

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02518113. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 8:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1b/Randomized Phase 2 Study to Evaluate LY3039478 in Combination With Dexamethasone in T-ALL/T-LBL Patients

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The main purpose of this study is to evaluate the safety of the study drug known as LY3039478 in combination with dexamethasone in participants with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma (T-ALL/T-LBL).

Study identification

NCT ID: NCT02518113
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Eli Lilly and Company; Industry
Enrollment: 36 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 2 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 1, 2015 (Actual)
Primary completion: Jan 15, 2018 (Actual)
Completion: Jan 15, 2018 (Actual)
Last update posted: Sep 11, 2019

2015 – 2018

United States locations

U.S. sites: 7
U.S. states: 6
U.S. cities: 7

Facility	City	State	ZIP	Site status
City of Hope National Medical Center	Duarte	California	91010-0269	—
Dana Farber Cancer Institute	Boston	Massachusetts	02215	—
Karmanos Cancer Institute	Detroit	Michigan	48201	—
Memorial Sloan Kettering Cancer Center	New York	New York	10065	—
Montefiore Medical Center	The Bronx	New York	10467	—
University of Pennsylvania Hospital	Philadelphia	Pennsylvania	19106	—
University of Texas MD Anderson	Houston	Texas	77030	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02518113, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 11, 2019 · Synced Nov 13, 2026